Journal Article

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

Louw, Cheryl, Carstens, Hannelie, van Niekerk, Neliëtte, Mans, Winel, Kapiga, Saidi, Van Baelen, Ben, Kotze, Philip, Gill, Katherine, Van Roey, Jens, Steytler, John, Solai, Leonard, Nuttall, Jeremy, Borremans, Maarten, Ntshele, Smangaliso, Windle, Kathleen, Nel, Annalene, Devlin, Brid, Gama, Cynthia, Kusemererwa, Sylvia, Rosenberg, Zeda, Smit, Marlie, Miti, Nokuthula, Mabude, Zonke, Spence, Patrick, Resseler, Sophie, Kamali, Anatoli, Vangeneugden, Tony, Bekker, Linda-Gail, Malherbe, Mariëtte, Isaacs, Michelle, Tempelman, Hugo, Parys, Wim, Russell, Marisa

2016

Overview

Preventing HIV-1 infection, especially with female-controlled approaches, is a high priority. In this trial in South Africa and Uganda, a dapivirine vaginal ring was associated with a rate of acquisition of HIV-1 infection that was approximately 30% lower than that with placebo. In 2014, approximately 36.9 million people worldwide were living with human immunodeficiency virus (HIV) infection. 1 Rates of new HIV infection among adolescent girls and young women remain high in Eastern and Southern Africa, 2 which underscores the need for the development of safe and effective tools against HIV infection that women initiate themselves. 3 – 5 Self-inserted vaginal rings, which provide a sustained release of antiretroviral drugs over time, have the potential to offer women a prevention option that does not require daily or pericoital use. 6 The International Partnership for Microbicides (IPM) developed a monthly self-administered vaginal ring that contains the nonnucleoside reverse-transcriptase . . .

• Publisher: Massachusetts Medical Society
• Subject: Adolescent / Adult / Age / Antiretroviral drugs / Disease prevention / Double-Blind Method / Drug Resistance, Viral / Female / HIV / HIV Infections - epidemiology / HIV Infections - prevention & control / HIV Seropositivity / HIV-1 - isolation & purification / Human immunodeficiency virus / Humans / Incidence / Microbicides / Middle Aged / Patient safety / Pregnancy / Pyrimidines - administration & dosage / Pyrimidines - adverse effects / Reverse Transcriptase Inhibitors - administration & dosage / Reverse Transcriptase Inhibitors - adverse effects / RNA, Viral - blood / Safety / Seroconversion / South Africa - epidemiology / Uganda - epidemiology / Vagina / Viral infections / Women / Young Adult